![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Zealand Pharma AS | NASDAQ:ZEAL | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 17.59 | 13.97 | 23.42 | 0 | 01:00:00 |
Company announcement – No. 50 / 2022
Zealand Pharma to Participate in Upcoming Investor Conferences
Copenhagen, Denmark and Boston, MA, U.S. November 8, 2022 – a Zealand Pharma A/S (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the company is scheduled to participate in the following investor conferences in November:
Jefferies London Healthcare ConferenceDate: Tuesday, November 15, 2022Presentation: 3:35 a.m. EST / 8:35 a.m. GMT / 9:35 a.m. CET
Evercore ISI Annual HealthCONx Conference (virtual)Date: Tuesday, November 29, 2022Presentation: 9:40 a.m. EST / 2:40 p.m. GMT / 3:40 p.m. CET
A live webcast of the presentations will be available on the "Events & Presentations" page in the Investor section of the Company's website at https://www.zealandpharma.com/events-presentations. A replay of the webcast will be archived on the Company's website following the presentation.
About Zealand Pharma A/SZealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 and headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.
Contacts:Anna Krassowska, PhDVice President, Investor Relations & Corporate CommunicationsZealand PharmaEmail: ank@zealandpharma.com
David Rosen (U.S. Media)Argot PartnersEmail: media@zealandpharma.com
1 Year Zealand Pharma AS Chart |
1 Month Zealand Pharma AS Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions